News
HealthDay News — Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within 6 months, according to a study ...
Designating GG1 on biopsy as noncancer without considering the prognostic values of adverse clinical features may lead to undertreatment and an increased risk of cancer-specific death in men with ...
Flu-linked ANE is associated with high morbidity and mortality in young and previously healthy children. The findings emphasize the need for prevention, early recognition, intensive treatment, and ...
The findings not only demonstrate the number of legal barriers faced by various sociodemographic groups but also highlight vulnerable populations with greater need of legal navigation, informing ...
Critics of most-favored-nation drug pricing have warned that it could reduce patient access to certain drugs, raise the prices of other drugs, and decrease research and development for new drugs.
The Food and Drug Administration (FDA) is requiring class-wide label changes for opioid medications to provide additional information on the risks associated with long-term use.
Meta-analysis of 10 studies indicate an average TTD of 3.5 years across all dementia types, with younger age at onset and frontotemporal dementia associated with longer diagnostic intervals.
A 58-year-old man presents for a routine annual physical. During the exam, he mentions an intermittent sensation like a “rush of anxiety” that begins in the abdomen and chest and radiates to the head.
Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.
These findings may partially reflect both structural barriers that delay timely diagnosis and the impact of local equity-driven initiatives that broaden colorectal cancer screening access.
In analysis of 5268 women from the first childbirth, the proportion of treated women began to decline 18 months before childbirth.
SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results